Axsome Malta v. Aurobindo Pharma: Solriamfetol Patents Dismissed Without Prejudice
Axsome Malta filed a patent infringement action in the District of New Jersey against Aurobindo Pharma asserting three patents covering solriamfetol oral tablets, marketed as Sunosi®. All claims, counterclaims, and affirmative defenses were dismissed without prejudice by stipulation after 202 days, with no costs or attorneys' fees awarded to either party.
Axsome's Sunosi® Patent Assertion Against Generic Challenger Ends Without Merits Decision
Axsome Malta, Ltd. filed suit on 14 November 2025 in the U.S. District Court for the District of New Jersey (Case No. 2:25-cv-17592) against Aurobindo Pharma, Ltd. The action asserted infringement of three U.S. patents — US12263145B2, US12390419B2, and US12318362B2 — each relating to solriamfetol oral tablets, the active ingredient in Axsome's branded product Sunosi®, a treatment used for excessive daytime sleepiness.
The case closed on 4 June 2026, 202 days after filing. The recorded basis of termination is dismissal without prejudice. The docket order, entered pursuant to Federal Rule of Civil Procedure 41(a)(1)(A)(ii), is styled as a stipulated dismissal of all claims, counterclaims, and affirmative defenses as between Axsome and Aurobindo, without costs or attorneys' fees to either party. The order further states that the District of New Jersey retains jurisdiction to enforce and resolve any disputes relating to the subject matter of the actions. The specific terms underlying the parties' agreement are not disclosed in the available record.
Resolution in under seven months, before any substantive merits ruling, is consistent with early-stage negotiated exits in pharmaceutical patent litigation. The retention of court jurisdiction suggests the parties contemplated ongoing obligations or potential future disputes relating to the same subject matter, though the nature of any such arrangement is not disclosed in the public record. It is also noted that the verdict text expressly carves out Aurobindo from any effect on claims against other defendants, indicating this was a multi-defendant matter and the litigation may continue against parties not named in this stipulation.
See Complete Case & Patent Analysis →Filing to Dismissed without Prejudice in 202 days
202 days from filing to closure — a relatively early resolution for a multi-patent pharmaceutical ANDA-type dispute in New Jersey
US12263145B2, US12390419B2 & US12318362B2 — Solriamfetol oral tablet patents
Any company developing, manufacturing, or seeking to commercialise a generic solriamfetol oral tablet product in the United States should treat these three patents as live enforcement risks. None were invalidated or found non-infringed in this proceeding, and Axsome has demonstrated willingness to assert them against generic challengers in federal court. ANDA filers in particular should conduct claim-by-claim FTO analysis before any Paragraph IV certification or launch decision.
Official order — verbatim text
The stipulated dismissal order, entered under Rule 41(a)(1)(A)(ii), resolves all claims and counterclaims between Axsome and Aurobindo without any merits determination on the three asserted patents. The without-prejudice designation means no claim preclusion attaches. The court's express retention of jurisdiction over subject-matter disputes is a notable procedural element. No infringement finding, validity ruling, or costs award was made.
Dismissed without prejudice: what the stipulated resolution means for both parties
Rule 41(a)(1)(A)(ii) stipulated dismissal without prejudice
Under Federal Rule of Civil Procedure 41(a)(1)(A)(ii), parties may jointly stipulate to dismiss an action without a court order. A dismissal without prejudice means the claims are not adjudicated on the merits and the plaintiff retains the right to re-file. The court here expressly retained jurisdiction to enforce and resolve disputes relating to the subject matter, which is a notable procedural feature of the order.
No merits adjudicationWithout prejudice: Axsome preserves its right to re-assert
A dismissal without prejudice is legally distinct from a dismissal with prejudice. With prejudice bars re-filing; without prejudice does not. The recorded basis of termination here is expressly without prejudice, meaning Axsome Malta retains the ability to bring future infringement claims on the same patents against Aurobindo in relation to solriamfetol. Whether any agreement between the parties affects that right in practice is not disclosed in the available public record.
Right to re-file preservedAurobindo exits without an adverse merits ruling — for now
Aurobindo Pharma obtains a dismissal without any court finding of infringement or validity determination on the three asserted patents. Because the dismissal is without prejudice, Aurobindo does not benefit from claim preclusion or issue preclusion based on this order. The stipulation also confirms no costs or attorneys' fees are owed to either party, meaning Aurobindo bears no financial penalty from this proceeding. The specific terms of the parties' arrangement, if any, are not disclosed in the public record.
No preclusive effectMulti-defendant litigation continues; Sunosi® IP enforcement remains live
The stipulation expressly states that dismissal as to Aurobindo does not affect claims, defenses, or counterclaims against any other defendant, confirming this is a multi-defendant proceeding. The three asserted patents covering solriamfetol tablets remain in force and unadjudicated. Generic pharmaceutical manufacturers and other ANDA filers in the solriamfetol space should note that Axsome's patent enforcement posture in the District of New Jersey appears active across multiple parties.
Active multi-defendant matterFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Axsome Malta, Ltd. | Company | /Search in Eureka ↗ |
| Defendant | Aurobindo Pharma, Ltd. | Company | /Search in Eureka ↗ |
| Plaintiff counsel | Alexander Lee Callo | Attorney | Counsel for Axsome Malta, Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Charles Michael Lizza | Attorney | Counsel for Axsome Malta, Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Sarah Ann Sullvian | Attorney | Counsel for Axsome Malta, Ltd.Search in Eureka ↗ |
| Plaintiff law firm | Saul Ewing LLP | Law Firm | Representing Axsome Malta, Ltd.Search in Eureka ↗ |
| Defendant counsel | WILLIAM HARE | Attorney | Counsel for Aurobindo Pharma, Ltd.Search in Eureka ↗ |
| Defendant law firm | McNeely, Hare & War LLP | Law Firm | Representing Aurobindo Pharma, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
R&D signals in the solriamfetol and CNS therapeutics patent space
Forward-looking patent intelligence on Axsome's solriamfetol IP estate, generic challenger filings, and innovation trends in the CNS sleep disorder therapeutics sector.
Axsome's solriamfetol patent estate: how deep is the fence?
Axsome asserted three distinct patents in this action, all recently issued. Mapping the full Axsome patent portfolio around solriamfetol — including any continuation chains, method-of-use filings, and pending applications — is essential for competitors assessing their generic entry window. The breadth and layering of the portfolio will determine how difficult it is to design around or challenge each patent independently.
Axsome IP estateFiling trends in dopamine/norepinephrine reuptake inhibitors for sleep disorders
Solriamfetol sits at the intersection of CNS stimulant pharmacology and sleep medicine. Patent filing activity around dopamine and norepinephrine reuptake inhibitors for narcolepsy and sleep apnea has grown as originators seek to extend exclusivity beyond compound patents. Tracking filing trends in this space can reveal where the next wave of generic challenges — and originator IP reinforcement — is likely to emerge.
CNS sleep disorder IP trendsAurobindo's CNS generics pipeline and patent challenge history
Aurobindo Pharma is a major global generic manufacturer with a broad U.S. ANDA filing history across CNS and other therapeutic areas. Understanding Aurobindo's patent challenge posture — including inter partes review filings, Paragraph IV certifications, and litigation outcomes in the CNS space — can help originators and competitors anticipate where Aurobindo is likely to push for generic entry next.
Aurobindo CNS genericsAdjacent innovation: novel formulations and delivery routes for solriamfetol
The three asserted patents focus on oral tablet formulations of solriamfetol. White space may exist in adjacent delivery modalities — extended-release formulations, modified dosage forms, or combination products — that fall outside the claim scope of the currently asserted patents. R&D teams exploring the solriamfetol space should map claim boundaries carefully to identify protectable differentiation opportunities.
Formulation white spaceSimilar pharmaceutical patent cases in the District of New Jersey
Browse related ANDA and pharmaceutical patent infringement cases in the District of New Jersey involving CNS and sleep disorder therapeutics.
What this case signals for the solriamfetol and CNS pharma IP landscape
Three recently issued patents, an early exit, and a carve-out for other defendants — Axsome's enforcement posture warrants close monitoring.
Three recently issued patents remain unadjudicated — enforcement risk persists
All three asserted patents (US12263145B2, US12390419B2, US12318362B2) were issued relatively recently and have not been tested on the merits in this action. Generic entrants and ANDA filers in the solriamfetol space should treat these patents as active enforcement tools and conduct thorough freedom-to-operate analysis before launch.
Multi-defendant structure signals a coordinated enforcement campaign
The stipulation's explicit carve-out — preserving claims against defendants other than Aurobindo — confirms Axsome is pursuing multiple generic challengers simultaneously. This is a common originator strategy to delay generic entry across the board. Competitors and their counsel should track the parallel dockets to understand the full scope of Axsome's litigation position on Sunosi®.
Axsome v Aurobindo — key questions answered
Axsome Malta asserted three U.S. patents: US12263145B2, US12390419B2, and US12318362B2. All three relate to solriamfetol oral tablets, the active ingredient in Axsome's branded product Sunosi®. The case was filed in the U.S. District Court for the District of New Jersey on 14 November 2025.
The case was dismissed without prejudice. The parties filed a stipulation under Federal Rule of Civil Procedure 41(a)(1)(A)(ii) dismissing all claims, counterclaims, and affirmative defenses between Axsome and Aurobindo, with no costs or attorneys' fees awarded to either party. The court retained jurisdiction over disputes relating to the subject matter. No merits determination was made on any of the three asserted patents.
A dismissal without prejudice means the claims are not adjudicated on the merits and no claim preclusion or issue preclusion attaches. Axsome retains the right to re-file infringement claims on the same patents against Aurobindo in the future. Whether any agreement between the parties affects that right in practice is not disclosed in the available public record.
No. The stipulation expressly states that dismissal as to Aurobindo does not result in dismissal of claims, defenses, or counterclaims against any other defendant. This confirms the litigation is a multi-defendant matter and that Axsome's patent enforcement campaign concerning Sunosi® continues against other parties in the District of New Jersey.
The stipulation states that the U.S. District Court for the District of New Jersey retains jurisdiction to enforce and resolve any disputes relating to the subject matter of the captioned actions. The specific reason for this retention and any underlying terms between the parties are not disclosed in the available public record.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.